Skip to main content
SpringerLink
Log in

Azithromycin cost effective in chlamydia if sequelae are considered

  • Drug Economics and Quality of Life
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Lea AP, Lamb HM. Azithromycin: a pharmacoeconomic review of its use as a single-dose regimen in the treatment of uncomplicated urogenital Chlamydia trachomatis infections in women. Drugs 1997 Nov; 12(5): 596–611

    CAS  Google Scholar 

  2. Jones RB. Chlamydia trachomatis (trachoma, perinatal infections, lymphogranuloma venereum, and other genital infections). In: Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas and Bennett’s Principles and practice of infectious diseases. 4th ed. v. 2. New York: Churchill Livingstone, 1995: 1679–93

  3. Workowski KA. Chlamydia trachomatis infection. In: Rakel RE, editor. Conn’s current therapy. Philadelphia: WB Saunders, 1996: 1062–4

    Google Scholar 

  4. Magid D, Douglas Jr JM, Schwartz JS. Doxycycline compared with azithromycin for treating women with genital Chlamydia trachomatis infections: an incremental cost-effectiveness analysis. Ann Intern Med 1996 Feb 15; 124: 389–99

    PubMed  CAS  Google Scholar 

  5. Haddix AC, Hillis SD, Kassler WJ. The cost-effectiveness of azithromycin for Chlamydia trachomatis infections in women. Sex Transm Dis 1995 Sep–Oct; 22: 274–80

    Article  PubMed  CAS  Google Scholar 

  6. Sclar DA, Tartaglione TA, Fine MJ. Overview of issues related to medical compliance with implications for the outpatient management of infectious diseases. Infect Agent Dis 1994; 3: 266–74

    CAS  Google Scholar 

  7. Grob PR. Antibiotic prescribing practices and patient compliance in the community. Scand J Infect Dis 1992; 83 Suppl.: 7–14

    CAS  Google Scholar 

  8. Urquhart J. Ascertaining how much compliance is enough with outpatient antibiotic regimens. Postgrad Med 1992; 68 Suppl. 3: S49–59

    Google Scholar 

  9. Genç M, Mårdh P-A. Cost-effective treatment of uncomplicated gonorrhoea including co-infection with Chlamydia trachomatis. Pharmacoeconomics 1997 Sep; 12: 374–83

    Article  PubMed  Google Scholar 

  10. Brookoff D. Compliance with doxycycline therapy for outpatient treatment of pelvic inflammatory disease. South Med J 1994; 87(11): 1088–91

    Article  PubMed  CAS  Google Scholar 

  11. Jordan WC. Doxycycline vs. tetracycline in the treatment of men with gonorrhea: the compliance factor. Sex Transm Dis 1981; 8 (2 Suppl.): 105–9

    Article  Google Scholar 

  12. Adair CD, Gunter M, Stovall TG, et al. Chlamydia in pregnancy: a randomised trial of azithromycin and erythromycin. Obstet Gynecol 1998;91: 165–8

    Article  PubMed  CAS  Google Scholar 

  13. Petitta A, Hart SM, Bailey EM, et al. Cost-effectiveness analysis of three alternative methods of providing drug therapy for the treatment of urogenital chlamydia infections in the emergency department [abstract no. 160]. Pharmacotherapy 1997; 17(5): 1105–5

    Google Scholar 

  14. Nuovo J, Melnikow J, Paliescheskey M, et al. Cost-effectiveness analysis of five different antibiotic regimens for the treatment of uncomplicated Chlamydia trachomatis cervicitis. J Am Board Fam Pract 1995 Jan–Feb; 8: 7–16

    PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Azithromycin cost effective in chlamydia if sequelae are considered. Drugs Ther. Perspect 12, 14–16 (1998). https://doi.org/10.2165/00042310-199812050-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-199812050-00005

Search

Navigation